ChemoCentryx, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating ChemoCentryx (NASDAQ: CCXI) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen.

Ademi LLP alleges ChemoCentryx’s financial outlook and prospects are excellent and yet ChemoCentryx holders will receive only $52 per share in cash, representing an enterprise value of approximately $3.7 billion. The transaction agreement unreasonably limits competing bids for ChemoCentryx by imposing a significant penalty if ChemoCentryx accepts a superior bid. ChemoCentryx insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of ChemoCentryx’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for ChemoCentryx.